EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of 31 congenital myasthenic syndrome patients with 3,4-diaminopyridine



Treatment of 31 congenital myasthenic syndrome patients with 3,4-diaminopyridine



Neurology 54(7 Supp 3): A395, April 11




(PDF 0-2 workdays service: $29.90)

Accession: 035980306

Download citation: RISBibTeXText



Related references

Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine. Neuromuscular Disorders 14(3): 202-207, 2004

Beneficial effects of 3,4-diaminopyridine in a 26-year-old woman with DOK7 congenital myasthenic syndrome who was originally diagnosed with facioscapulohumeral dystrophy. Rinsho Shinkeigaku 54(7): 561-564, 2015

3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. New England Journal of Medicine 321(23): 1567-1571, 1989

3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Review of Clinical Immunology 6(6): 867-874, 2011

The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine. Revista Clinica Espanola 192(7): 354-355, 1993

Oral 3 4 diaminopyridine in the treatment of the lambert eaton myasthenic syndrome. Journal of Neurology Neurosurgery & Psychiatry 47(9): 1052-1053, 1984

3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Annals of the New York Academy of Sciences 841: 811-816, 1998

Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine. Medicina Clinica 104(4): 156-156, 1995

Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 96(8): 1709-1711, 2007

3,4-Diaminopyridine as long-term treatment in Lambert-Eaton myasthenic syndrome. Aktuelle Neurologie 20(2): 62-64, 1993

Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurologica Scandinavica 88(2): 136-140, 1993

3,4-diaminopyridine, an orphan drug in the treatment of Lambert-Eaton Myasthenic Syndrome. Pfluegers Archiv European Journal of Physiology 431(6 SUPPL 2): R186, 1996

In vitro effect of 3,4-diaminopyridine on neuromuscular transmission in muscle biopsies of patients with different types of congenital myasthenic syndromes. Neurology 54(7 Supp 3): A395, April 11, 2000

3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome. Pflugers Archiv 431(6 Suppl 2): R295-R296, 1996